ZHB114
/ Zonhon Biopharma Institute, Qianhong Bio-Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 26, 2025
Preclinical study of a novel long-acting receptor-biased rhIL-2 drug with sustained activation of cytotoxic T cells
(AACR 2025)
- "Compared with other analogous drugs in development, ZHB114 is more potent and is expected to become a novel long-acting IL-2 agent for tumor immunotherapy, with fewer side effects."
Preclinical • Genito-urinary Cancer • Melanoma • Oncology • Renal Cell Carcinoma • Solid Tumor • IL2 • PD-1
1 to 1
Of
1
Go to page
1